First in Texas: UTHealth Houston and Memorial Hermann Introduce New FDA-Approved Tricuspid Valve System
This month, UTHealth Houston and Memorial Hermann have made history by becoming the first institution in the state to utilize the newly FDA-approved Edwards’ EVOQUE Tricuspid Valve Replacement System.
Our involvement in the TRISCEND II Clinical Trial for the Edwards’ EVOQUE Tricuspid Valve Replacement System marked a significant milestone in our journey towards this achievement. As one of the leading institutions to participate in and contribute to the success of the trial, it was a natural progression for our team to be the inaugural adopters in the State of Texas for the EVOQUE system once it received FDA approval. This seamless transition from trial participation to clinical implementation speaks volumes about our expertise, dedication to patient care, and our relentless pursuit of excellence in cardiovascular surgery.
We’re immensely proud of our dedicated team whose expertise and commitment to excellence have made this milestone possible.